# A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct07098338/  
OnCo record `nct07098338` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rilvegostomig, Ramucirumab, Datopotamab deruxtecan in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.

## Summary

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07098338 by AstraZeneca, with 278 participants planned, started 2025-08-07 and due to reach its primary completion in 2029-04-06. Interventions recorded: Rilvegostomig, Ramucirumab, Dato-DXd. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07098338
- Phase: 2
- Setting: An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
- Sponsor: AstraZeneca
- Enrolled: 278

## Sources

- ClinicalTrials.gov NCT07098338: https://clinicaltrials.gov/study/NCT07098338

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07098338.json